Clinical Trial Update: Central European Society for Anticancer Research (CESAR) Study of Paclitaxel Therapeutic Drug Monitoring [Phase 3]

View source ↗

Summary

A Phase 3 study (CESAR) evaluating therapeutic drug monitoring for paclitaxel in non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• PACLITAXEL (PACLITAXEL)
• Taxol (paclitaxel)

Snippet

Sponsor: Central European Society for Anticancer Drug Research | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 3 | Status: COMPLETED